{"filing":{"accession_number":"0001193125-26-329570","cik":"0001807120","ticker":"DSGN","company_name":"Design Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"dsgn-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526329570/dsgn-20260803.htm"},"events":[{"id":23322,"run_id":21088,"accession_number":"0001193125-26-329570","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Design Therapeutics issued a press release on August 3, 2026 announcing financial results for the three and six months ended June 30, 2026, including R\u0026D expenses of $16.4 million, G\u0026A expenses of $5.8 million, net loss of $20.2 million for Q2, and cash position of $207.4 million. The filing includes condensed statements of operations and balance sheets, which are standard components of quarterly earnings disclosures under Item 2.02.","company_name":"Design Therapeutics, Inc.","ticker":"DSGN","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23519,"accession_number":"0001193125-26-329570","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Design Therapeutics issued a press release on August 3, 2026 announcing financial results for the three and six months ended June 30, 2026, including R\u0026D expenses of $16.4 million, G\u0026A expenses of $5.8 million, net loss of $20.2 million for Q2, and cash position of $207.4 million. The filing includes condensed statements of operations and balance sheets, which are standard components of quarterly earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:19:43.435041+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23519,"accession_number":"0001193125-26-329570","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Design Therapeutics issued a press release on August 3, 2026 announcing financial results for the three and six months ended June 30, 2026, including R\u0026D expenses of $16.4 million, G\u0026A expenses of $5.8 million, net loss of $20.2 million for Q2, and cash position of $207.4 million. The filing includes condensed statements of operations and balance sheets, which are standard components of quarterly earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:19:43.435041+00:00","company_name":"Design Therapeutics, Inc.","ticker":"DSGN","filing_date":"2026-08-03"}]}